-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Glypican-3 -X- _ B-Intervention
( -X- _ I-Intervention
GPC3 -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
cell -X- _ O
surface-bound -X- _ O
proteoglycan -X- _ O
which -X- _ O
has -X- _ O
been -X- _ O
identified -X- _ O
as -X- _ O
a -X- _ O
potential -X- _ O
biomarker -X- _ O
candidate -X- _ O
in -X- _ O
hepatocellular -X- _ B-Patient
carcinoma -X- _ I-Patient
, -X- _ O
lung -X- _ B-Patient
carcinoma -X- _ I-Patient
, -X- _ O
severe -X- _ B-Patient
pneumonia -X- _ I-Patient
, -X- _ O
and -X- _ O
acute -X- _ B-Patient
respiratory -X- _ I-Patient
distress -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
ARDS -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
our -X- _ O
review -X- _ O
is -X- _ O
to -X- _ O
evaluate -X- _ O
whether -X- _ O
GPC3 -X- _ O
has -X- _ O
utility -X- _ O
as -X- _ O
a -X- _ O
disease-specific -X- _ O
biomarker -X- _ O
, -X- _ O
to -X- _ O
discuss -X- _ O
the -X- _ O
potential -X- _ O
involvement -X- _ O
of -X- _ O
GPC3 -X- _ O
in -X- _ O
cell -X- _ O
biology -X- _ O
, -X- _ O
and -X- _ O
to -X- _ O
consider -X- _ O
the -X- _ O
changes -X- _ O
of -X- _ O
GPC3 -X- _ O
gene -X- _ O
and -X- _ O
protein -X- _ O
expression -X- _ O
and -X- _ O
regulation -X- _ O
in -X- _ O
hepatocellular -X- _ B-Patient
carcinoma -X- _ I-Patient
, -X- _ O
lung -X- _ O
cancer -X- _ O
, -X- _ O
severe -X- _ B-Patient
pneumonia -X- _ I-Patient
, -X- _ O
and -X- _ O
ARDS. -X- _ B-Patient
RESULTS -X- _ O
: -X- _ O
Immunohistochemical -X- _ O
studies -X- _ O
have -X- _ O
suggested -X- _ O
that -X- _ O
over-expression -X- _ O
of -X- _ O
GPC3 -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
a -X- _ O
poorer -X- _ O
prognosis -X- _ O
for -X- _ O
hepatocellular -X- _ B-Patient
carcinoma -X- _ I-Patient
patients. -X- _ O
Expression -X- _ O
of -X- _ O
GPC3 -X- _ O
leads -X- _ O
to -X- _ O
an -X- _ O
increased -X- _ O
apoptosis -X- _ O
response -X- _ O
in -X- _ O
human -X- _ O
lung -X- _ B-Patient
carcinoma -X- _ I-Patient
tumor -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
is -X- _ O
considered -X- _ O
to -X- _ O
be -X- _ O
a -X- _ O
candidate -X- _ O
lung -X- _ O
tumor -X- _ O
suppressor -X- _ O
gene. -X- _ O
Increased -X- _ O
serum -X- _ O
levels -X- _ O
of -X- _ O
GPC3 -X- _ O
have -X- _ O
been -X- _ O
demonstrated -X- _ O
in -X- _ O
ARDS -X- _ B-Patient
patients -X- _ O
with -X- _ O
severe -X- _ B-Patient
pneumonia. -X- _ I-Patient
CONCLUSIONS -X- _ O
: -X- _ O
Glypican-3 -X- _ B-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
considered -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
clinically -X- _ I-Outcome
useful -X- _ I-Outcome
biomarker -X- _ I-Outcome
in -X- _ I-Outcome
hepatocellular -X- _ I-Outcome
carcinoma -X- _ I-Outcome
, -X- _ I-Outcome
lung -X- _ I-Outcome
carcinoma -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
ARDS -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
further -X- _ I-Outcome
research -X- _ I-Outcome
is -X- _ I-Outcome
needed -X- _ I-Outcome
to -X- _ I-Outcome
confirm -X- _ I-Outcome
and -X- _ I-Outcome
expand -X- _ I-Outcome
on -X- _ I-Outcome
these -X- _ I-Outcome
findings -X- _ I-Outcome
. -X- _ O

